AHR and hepatocellular carcinoma: Moreover, when hepatoma cells (SK-Hep1) were treated with TCDD, a prototypical AHR ligand, expressions of HDAC8 and the classical AHR target gene CYP1B1 were increased in hepatoma cells in a time-dependent manner, both at protein level (Figure 3B).